Ceredase Related Published Studies
Well-designed clinical trials possibly related to Ceredase (Alglucerase)
Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. [2002.03]
Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. [1995.01.01]
Developing and testing a multimedia presentation of a health-state description. [1994.10]
Other research related to Ceredase (Alglucerase)
Use of direct fluorescence labeling and confocal microscopy to determine the biodistribution of two protein therapeutics, Cerezyme and Ceredase. [2010.07]
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. [2009.02]
Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase. [2001.11.01]
Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. [1999.04]
Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. [1999.03.15]
[Uveitis masquerade syndrome in Gaucher disease. Causal treatment by alglucerase substitution therapy] [1998.12]
[Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months] [1998.12]
Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease. [1997.12]
Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. [1997.08]
[Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease] [1997.06]
Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. [1996.07]
Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. [1995.06.10]
Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages. [1995.03]
Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease. [1995.01]
HCG contamination of alglucerase: clinical implications in low-dose regimen. [1994.11]
[Course of a case of Gaucher's disease type 1 treated over a year with glucocerebrosidase (Ceredase)] [1993]
A less costly regimen of alglucerase to treat Gaucher's disease. [1992.12.03]
Alglucerase. A review of its therapeutic use in Gaucher's disease. [1992.07]
Other possibly related research studies
Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. [2007.07]
[Gaucher's disease--ocular manifestation and treatment] [2006]
Substrate reduction therapy of glycosphingolipid storage disorders. [2006.04]
Limitations of enzyme replacement therapy: current and future. [2006.04]
Lysosomal storage diseases: natural history and ethical and economic aspects. [2006.07]
Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. [2006.03]
Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: monocytes from Gaucher disease patients as a model. [2005.06]
Bilateral lung transplant in Gauchers type-1 disease. [2005.04]
Enzyme replacement therapy for Gaucher disease in Australia. [2005.03]
Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi. [2003.08]
Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1. [2003.04]
[Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI] [2003.04.20]
Rebound hepatosplenomegaly in type 1 Gaucher disease. [2003.02]
Cessation of enzyme replacement therapy in Gaucher disease. [2002.11]
Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia. [2002.09]
[French results of enzyme replacement therapy in Gaucher's disease] [2002]
Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher's disease. [2002.09]
Type I Gaucher disease in children with and without enzyme therapy. [2002.09]
Cemented revision total hip arthroplasty with impaction bone grafting in Gaucher's disease. [2002.08]
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. [2002.08.01]
Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy. [2002.07]
Gaucher's disease and fatal hepatic fibrosis despite prolonged enzyme replacement therapy. [2002.06]
Bone complications in children with Gaucher disease. [2002]
Response of Gaucher bone disease to enzyme replacement therapy. [2002]
Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. [2001.11]
Early-onset severe neurological involvement and D409H homozygosity in Gaucher disease: outcome of enzyme replacement therapy. [2002.01]
[Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement] [2001.10]
Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. [2001.09]
Lung involvement and enzyme replacement therapy in Gaucher's disease. [2001.08]
Neurological features in Gaucher's disease during enzyme replacement therapy. [2001.02]
Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. [2001.01]
Pregnancy after avascular necrosis of the femur complicating Gaucher's disease. [2001.01]
A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. [2001.01]
Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. [2000.10]
Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. [2000.08]
Metaphyseal undertubulation in gaucher disease: resolution at MRI in a patient undergoing enzyme replacement therapy. [2000.01]
Quality of life assessment in adults with type 1 Gaucher disease. [1999.05]
T cell numbers relate to bone involvement in Gaucher disease. [1999.04]
Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. [1998.05.23]
Enzyme therapy in Gaucher disease type 2: an autopsy case. [1998.10]
Splenic abscess in a patient with type 3 Gaucher's disease receiving enzyme replacement therapy. [1999.02]
Enzyme replacement therapy for Gaucher's disease: the early Canadian experience. [1998.11.17]
Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease. [1998.09]
The impact of Gaucher disease and its treatment on quality of life. [1998.08]
Recurrence of the D409H mutation in Spanish Gaucher disease patients: description of a new homozygous patient and haplotype analysis. [1998.09]
Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT). [1998.07]
Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. [1998.09]
Pulmonary involvement of Gaucher's disease in children: a common presentation in Saudi Arabia. [1998.03]
Enzyme therapy for Gaucher disease: the first 5 years. [1998.06]
Gaucher's disease and pregnancy. [1998.05]
Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR. [1998.04]
Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy. [1998.03.23]
Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. [1997.12]
Use of enzyme replacement therapy for Gaucher disease during pregnancy. [1997.12]
Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. [1997.10]
Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. [1997.09]
Should repeated partial splenectomy be attempted in patients with hematological diseases? Technical pitfalls and causes of failure in Gaucher's disease. [1997.09]
Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. [1997.08]
Gaucher disease: enzyme therapy in the acute neuronopathic variant. [1997.07.11]
Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy. [1997.06]
Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. [1997.03]
[Enzyme replacement therapy: a new treatment concept in Gaucher disease] [1997.02.14]
[Enzyme therapy in children with severe forms of Gaucher's disease] [1997.02.05]
Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy. [1997]
Gaucher's disease in pregnancy. [1996.09]
Regression of skeletal changes in type 1 Gaucher disease with enzyme replacement therapy. [1996.07]
Gaucher's disease: a review. [1996.04]
Coagulation abnormalities in patients with Gaucher's disease: effect of therapy. [1996.03]
Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. [1996.02]
Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. [1996]
Pathological findings in Gaucher disease type 2 patients following enzyme therapy. [1995.09]
Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. [1995.08]
The clinical course of treated and untreated Gaucher disease. A study of 45 patients. [1995]
Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy. [1995]
Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. [1994.12.17]
Glucocerebrosidase for treatment of Gaucher's disease: first German long-term results. [1994.10]
Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. [1994.07]
Current status of orphan disease drug development. [1994.04]
[Type I Gaucher's disease: clinical, evolutive and therapeutic features in 8 cases] [1994.02]
Subtotal splenectomy for Gaucher's disease: a follow-up study. [1993.12]
|